Alcon Shareholders Conditionally Elect Novartis-Designated Directors
H U ENENBERG, Switzerland – August 16, 2010 – Alcon, Inc. (NYSE:ACL) announced the following
action was taken by shareholders at the extraordinary general meeting of the Alcon shareholders held today in
These elections will become effective only upon the consummation of the acquisition by Novartis of all
common shares of Alcon that are beneficially owned by Nestlé.
This action was in satisfaction of a condition under the Purchase and Option Agreement and was also
required by the Shareholders Agreement, each dated April 6, 2008 and entered into between Nestlé and
Alcon, Inc. is the world’s leading eye care company, with sales of approximately $6.5 billion in 2009. Alcon,
which has been dedicated to the ophthalmic industry for 65 years, researches, develops, manufactures and
markets pharmaceuticals, surgical equipment and devices, contacts lens solutions and other vision care products
that treat diseases, disorders and other conditions of the eye. Alcon operates in 75 countries and sells products
in 180 markets. For more information on Alcon, Inc., visit the Company’s web site at www.alcon.com .
# # #
· Conditional election of directors designated by Novartis AG (“Novartis”) to replace directors
designated by Nestlé S.A. (“Nestlé”) if and when Novartis acquires Nestlé’s remaining shares of
Alcon. The directors designated by Novartis and conditionally elected by shareholders are:
- Dr. Enrico Vanni until 2011
- Mr. Norman Walker until 2011
- Dr. Paul Choffat until 2012
- Dr. Urs Baerlocher until 2013
- Dr. Jacques Seydoux until 2013
Caution Concerning Forward-Looking Statements.
This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements principally relate to s